黑料吃瓜群网

This 鈥� Tuesday, 28 July 2020 鈥� Australia鈥檚 leading drug and infectious disease organisations will gather in the virtual world to re-engage on the elimination of hepatitis C.

The (WHO) has set the global goal of eliminating hepatitis C as a public health threat by 2030. Australia is on track to become one of the first countries to achieve this; however, the COVID-19 pandemic and related social isolation has impacted drug use, drug and hepatitis C treatment services, and the health of people who use drugs. This has put an increased risk on new hepatitis transmission, access to treatment and the 2030 elimination goals.

The (AIVL), , the (APSAD), the and (NDARC) at UNSW Sydney, have partnered to address what COVID-19 will mean for hepatitis C elimination in Australia.

Hepatitis Australia CEO Carrie Fowlie said, 鈥淗epatitis C is a blood-borne virus, and people who inject drugs are a crucial priority population.

鈥淣ot only is there a risk that the WHO 2030 elimination goal could be set back, but more immediate negative impacts could be experienced by people at risk of contracting hepatitis or seeking hepatitis treatment in Australia due to current and future social, health and policy changes.鈥�

AIVL CEO Melanie Walker said some of the new regulations and social requirements are impossible for people who use drugs to abide by.

鈥淧eople who use drugs need to attend needle and syringe programs (NSPs) and be able to have ongoing access to the full range of harm reduction, pharmacotherapy and other drug and hepatitis treatments,鈥� Walker said.

鈥淚f people who use drugs cannot access these services, we could see an increase in sharing of injecting equipment, which could lead to increased cases of hepatitis C and compound the negative health outcomes already experienced by this group.鈥�

In the newly released , illicit drug use was responsible for 75% of Australia鈥檚 acute hepatitis C burden of disease.

Professor Greg Dore, Head of Viral Hepatitis Clinical Research Program at the Kirby Institute, UNSW Sydney, said there had been encouraging recent data from the on the prevalence of active hepatitis C infection in people who inject drugs, showing a decline from 51% to 18% between 2015 and 2019.

鈥淗owever, despite these declines in number of people with hepatitis C, continued declines in numbers being treated through 2019 and into 2020 compromises the achievement of WHO elimination goals,鈥� Professor Dore said.

鈥淢ore strategies are needed to raise awareness of the need for testing and availability of new hepatitis C treatments to eliminate hepatitis C by 2030.鈥�

In an NDARC study of 702 people who used drugs during COVID-19 restrictions and lockdown, it was found only 24% were able to avoid sharing drug injecting equipment.

Director of NDARC at UNSW Sydney Professor Michael Farrell said the research shows that people who use drugs want to limit their risk of contracting viral diseases like COVID-19 and hepatitis C, but this can be challenging due to a range of factors.

鈥淲e need to continue to find solutions that support people who use drugs to ensure hepatitis C elimination remains a priority.鈥�

About the online event

The online event will be facilitated by health reporter Dr Norman Swan, bringing together affected communities, doctors, scientists, health and community workers, researchers and the public to discuss the immense challenges COVID-19 brings to hepatitis C elimination and the health of people who use drugs, and to discuss strategies to ensure Australia stays on track to become one of the first countries in the world to eliminate hepatitis C.

What: Dual pandemics 鈥� what will COVID-19 mean for hepatitis C elimination?

When: Tuesday, 28 July 2020

Time: 12.30鈥�2.30 pm

Web: .

Image credit: 漏stock.adobe.com/au/Vitalii Vodolazskyi